{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:44:21Z","timestamp":1773240261178,"version":"3.50.1"},"reference-count":25,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Oral bisphosphonates comprise the most widely prescribed class of antiosteoporotic drugs. Recent reports, however, propose a link between prolonged bisphosphonate use and atypical, low-energy, subtrochanteric fractures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>The aim was to describe the clinical course of a patient treated long-term with alendronate who developed subtrochanteric stress fractures and to propose a hypothesis to explain teriparatide's potential contribution in healing the patient's stress fractures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Magnetic resonance imaging (MRI) showed classical bilateral stress fractures of the mid-femora. Baseline serum 25-hydroxyvitamin D3 was low; bone-specific alkaline phosphatase was slightly increased; serum carboxyterminal cross-linking telopeptide of bone collagen and urine aminoterminal cross-linking telopeptide of bone collagen were low to normal, as was serum osteocalcin. Dual-energy x-ray absorptiometry showed osteopenic vertebral bone mineral density and osteoporotic hip values. Treatment with large doses of oral vitamin D increased serum 25-hydroxyvitamin D3 to normal within 2 months, after which it remained in the normal range with maintenance doses. Thigh pain, present as an initial symptom, intensified, and the MRI appearance of the fractures worsened. Teriparatide treatment commenced, and 6 months later, a repeat MRI showed decreased edema at the fracture sites with faint cortical bridging. Thigh pain and lower limb weakness disappeared over the next year, and complete fracture healing was established (MRI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Based upon the chronology of fracture healing in our patient and published evidence that teriparatide heals stress fractures in a rat model, we think that teriparatide was probably primary in this patient's positive response to therapy, with calcium, vitamin D therapy, and alendronate discontinuation playing secondary roles.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2010-2520","type":"journal-article","created":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T02:02:26Z","timestamp":1300932146000},"page":"1627-1632","source":"Crossref","is-referenced-by-count":95,"title":["Teriparatide, Vitamin D, and Calcium Healed Bilateral Subtrochanteric Stress Fractures in a Postmenopausal Woman with a 13-Year History of Continuous Alendronate Therapy"],"prefix":"10.1210","volume":"96","author":[{"given":"Stephen J.","family":"Gomberg","sequence":"first","affiliation":[{"name":"West Oaks Orthopaedic Associates (S.J.G.), Thousand Oaks, California 91361;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna L.","family":"Wustrack","sequence":"additional","affiliation":[{"name":"University of California, San Francisco (R.L.W., C.D.A., D.M.B.), San Francisco, California 94143;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[{"name":"Universita Campus Bio-Medico di Roma (N.N.), 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude D.","family":"Arnaud","sequence":"additional","affiliation":[{"name":"University of California, San Francisco (R.L.W., C.D.A., D.M.B.), San Francisco, California 94143;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis M.","family":"Black","sequence":"additional","affiliation":[{"name":"University of California, San Francisco (R.L.W., C.D.A., D.M.B.), San Francisco, California 94143;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071616565855400_B1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2020071616565855400_B2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2020071616565855400_B3","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2020071616565855400_B4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Sub-trochanteric insufficiency fractures in patients on alendronate therapy: a caution.","volume":"89","author":"Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"key":"2020071616565855400_B5","first-page":"485","article-title":"Sequential non-traumatic femoral shaft fractures in a patient on long term alendronate.","volume":"13","author":"Cheung","year":"2007","journal-title":"Hong Kong Med J"},{"key":"2020071616565855400_B6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low energy femoral shaft fractures associated with alendronate use.","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"key":"2020071616565855400_B7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"2020071616565855400_B8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","article-title":"Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.","volume":"85","author":"Armamento-Villareal","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"2020071616565855400_B9","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1359\/jbmr.090408","article-title":"Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.","volume":"24","author":"Somford","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071616565855400_B10","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.2106\/JBJS.H.01774","article-title":"Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.","volume":"91","author":"Capeci","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"2020071616565855400_B11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low energy femoral fractures with prolonged bisphosphonate use: a case control study.","volume":"20","author":"Lenart","year":"2009","journal-title":"Osteoporos Int"},{"key":"2020071616565855400_B12","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071616565855400_B13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00198-009-1012-0","article-title":"Bisphosphonate associated femoral fracture: implications for management in patients with malignancies.","volume":"21","author":"Napoli","year":"2010","journal-title":"Osteoporos Int"},{"key":"2020071616565855400_B14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00005373-199707000-00027","article-title":"Specific features associated with femoral shaft fractures caused by low energy trauma.","volume":"43","author":"Salminen","year":"1997","journal-title":"J Trauma"},{"key":"2020071616565855400_B15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1359\/jbmr.090527","article-title":"Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.","volume":"24","author":"Dobnig","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071616565855400_B16","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility.","volume":"93","author":"Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565855400_B17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","article-title":"Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register based national cohort study.","volume":"24","author":"Abrahamsen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071616565855400_B18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMc0910389","article-title":"Atypical fractures and bisphosphonate use.","volume":"362","author":"Girgis","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071616565855400_B19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1302\/0301-620X.92B5.22941","article-title":"A rational approach to management of alendronate-related subtrochanteric fractures.","volume":"92","author":"Das De","year":"2010","journal-title":"J Bone Joint Surg Br"},{"key":"2020071616565855400_B20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bone.2009.10.009","article-title":"Temporal pattern of gene expression and histology of stress fracture healing.","volume":"46","author":"Kidd","year":"2010","journal-title":"Bone"},{"key":"2020071616565855400_B21","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure.","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2020071616565855400_B22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric properties.","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071616565855400_B23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071616565855400_B24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071616565855400_B25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2010.05.015","article-title":"Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.","volume":"47","author":"Sloan","year":"2010","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/6\/1627\/9085985\/jcem1627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/6\/1627\/9085985\/jcem1627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:28:19Z","timestamp":1594956499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/6\/1627\/2834030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,1]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2010-2520","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,1]]}}}